Telpoeptide integrates cov teebmeem ntawm ob incretins-glucose-nyob ntawm insulinotropic peptide (GIP) thiab glucagon-zoo li peptide-1 (GLP-1)- rau hauv ib qho molecule. Nws yog ib lub lim tiam formulation, txhaj ib lub lim tiam. Raws li qhov tseeb WHO cov lus qhia nyob rau lub Kaum Ob Hlis 2025, GLP-1 cov tshuaj, los ntawm kev ua raws li cov txheej txheem ntawm kev ua ntawm cov tshuaj hormones hauv kev tswj kev qab los noj mov, ntshav qabzib, thiab kev zom zaub mov, tau lees paub tias yog ib feem tseem ceeb ntawm kev kho mob rog rog.
Telpoeptide lub ntsiab kom zoo dua yog nyob rau hauv nws dual receptor agonist ua:
1. Ua kom muaj GIP receptors: Txhawb cov insulin secretion thiab inhibits glucagon tso tawm, ncaj qha txo cov ntshav qabzib;
2. Ua kom muaj GLP-1 receptors: Ua rau lub plab zom mov qeeb, txo kev noj zaub mov (txo qis calorie nqus), thiab ua kom muaj zog insulin ib txhij (txhim kho kev siv cov piam thaj). Cov txheej txheem no ua rau nws zoo dua rau tib lub hom phiaj GLP-1 receptor agonists (xws li smegglutinide) hauv kev txo cov ntshav qabzib (txo HbA1c) thiab poob phaus.